FDA Approves First COVID-19 Treatment for Young Children

4/26/22 — The FDA expanded the approval of the COVID-19 treatment Veklury (remdesivir) to include pediatric patients ages 28 days and older with positive results of direct SARS-CoV-2 viral testing, who are hospitalized, or have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19. This makes Veklury the first approved COVID-19 treatment for children less than 12 years of age. As a result of this approval, the agency also revoked the emergency use authorization for Veklury that previously covered this pediatric population. Read the FDA announcement.